Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics

A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (“Bain Capital”), and RA Capital Management (“RA Capital”) together with Sarepta Therapeutics, Inc, a leader in precision genetic medicine for rare diseases, announced on October 22nd a $107 million Series A financing to create AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases. The private financing round includes a $15 million equity investment from Sarepta. AavantiBio will pursue a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease characterized by cardiac and central nervous system dysfunction

For further information, see (https://investorrelations.sarepta.com/news-releases/news-release-details/gene-therapy-company-aavantibio-launches-107-million-series)

3D illustration. Colorful DNA molecule. Concept image of a structure of the genetic code.

Leave a Reply

Your email address will not be published. Required fields are marked *